- Home
- NSTS vs CNTX Comparison
NSTS vs CNTX Comparison
Compare NSTS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- CNTX
- Stock Information
- Founded
- NSTS 1921
- CNTX 2015
- Country
- NSTS United States
- CNTX United States
- Employees
- NSTS N/A
- CNTX N/A
- Industry
- NSTS Savings Institutions
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- CNTX Health Care
- Exchange
- NSTS Nasdaq
- CNTX Nasdaq
- Market Cap
- NSTS 65.5M
- CNTX 78.0M
- IPO Year
- NSTS N/A
- CNTX 2021
- Fundamental
- Price
- NSTS $12.33
- CNTX $0.64
- Analyst Decision
- NSTS
- CNTX Strong Buy
- Analyst Count
- NSTS 0
- CNTX 5
- Target Price
- NSTS N/A
- CNTX $5.50
- AVG Volume (30 Days)
- NSTS 4.9K
- CNTX 324.1K
- Earning Date
- NSTS 08-08-2025
- CNTX 08-06-2025
- Dividend Yield
- NSTS N/A
- CNTX N/A
- EPS Growth
- NSTS N/A
- CNTX N/A
- EPS
- NSTS N/A
- CNTX N/A
- Revenue
- NSTS $9,115,000.00
- CNTX N/A
- Revenue This Year
- NSTS N/A
- CNTX N/A
- Revenue Next Year
- NSTS N/A
- CNTX N/A
- P/E Ratio
- NSTS N/A
- CNTX N/A
- Revenue Growth
- NSTS 78.72
- CNTX N/A
- 52 Week Low
- NSTS $9.37
- CNTX $0.49
- 52 Week High
- NSTS $13.32
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- NSTS 55.78
- CNTX 49.68
- Support Level
- NSTS $12.24
- CNTX $0.56
- Resistance Level
- NSTS $12.33
- CNTX $0.66
- Average True Range (ATR)
- NSTS 0.12
- CNTX 0.06
- MACD
- NSTS -0.03
- CNTX 0.01
- Stochastic Oscillator
- NSTS 92.12
- CNTX 29.03
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.